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A B S T R A C T
Background
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is terminal, progressive neurological condition for which
there are no curative treatments. Among people with ALS/MND, fatigue is a common and debilitating symptom, which is characterised by
reversible motor weakness and whole-body tiredness that is only partially relieved by rest. The e>ectiveness of pharmacological or non-
pharmacological treatments for fatigue in ALS/MND is not yet established.
Objectives
To assess the e>ects of pharmacological and non-pharmacological interventions for fatigue in ALS/MND.
Search methods
We searched the following databases on 5 September 2017: Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase,
PsycINFO, CINAHL Plus, and ERIC. We also searched two clinical trials registries.
Selection criteria
We selected randomised and quasi-randomised controlled trials of any intervention which sought to reduce fatigue for people with ALS/
MND. We included studies if reduction in fatigue was a primary or secondary outcome of the trial.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane.
Main results
We included one pharmacological (modafinil) study and three non-pharmacological studies (resistance exercise, respiratory exercise, and
repetitive transcranial magnetic stimulation (rTMS)), involving a total of 86 participants with ALS/MND. None of the included studies were
free from risk of bias. Since there was only one trial for each intervention, no meta-analysis was possible. All studies assessed fatigue using
the Fatigue Severity Scale (FSS; scale from 9 to 63, higher scores indicate more fatigue). Information for assessing bias was oMen lacking
in study reports, making the risk of bias unclear across several domains in all trials. Blinding of participants was not possible in exercise
trials, but the outcome assessment was blinded.
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We found very low-quality evidence suggesting possible improvements in fatigue for modafinil treatment versus placebo (MD -11.00, 95%
CI -23.08 to 1.08), respiratory exercise versus a sham intervention (MD -9.65, 95% CI -22.04 to 2.73), and rTMS versus sham rTMS (data
not provided), which warrant further investigation to clarify the e>icacy of these treatments for fatigue in ALS/MND. We found no clear
improvements in fatigue for resistance exercise versus usual care (MD 0.20, 95% CI -10.98 to 11.38; very low-quality evidence).
Three participants in the modafinil group dropped out of the modafinil study, two citing issues with headache and one with chest tightness;
other adverse e>ects were anxiety, nausea, dizziness, and sialorrhoea (probably ALS-related). The trials reported no adverse e>ects of
exercise or rTMS.
We cannot be certain about the e>ects of any of the interventions studied because of imprecision (small numbers of participants, wide
CI), and possible study limitations.
Authors' conclusions
It is impossible to draw firm conclusions about the e>ectiveness of interventions to improve fatigue for people with ALS/MND as there are
few randomised studies, and the quality of available evidence is very low.
P L A I N   L A N G U A G E   S U M M A R Y
Treatments for extreme tiredness and lack of energy (fatigue) in amyotrophic lateral sclerosis/motor neuron disease
Review question
What are the e>ects of treatments for fatigue in people living with amyotrophic lateral sclerosis (ALS) compared to no treatment or placebo?
Background
ALS, which is also known as motor neuron disease (MND), is a condition in which the nerves that control movement stop working. People
experience problems moving their limbs, maintaining posture, swallowing, and breathing, which worsen over time and shorten life. The
cause is unknown, and there is no cure. People living with ALS/MND oMen experience fatigue, which can cause distress and reduce quality
of life. Fatigue can have many causes, including respiratory problems, medication, malnutrition, and depression. Our focus in this review
was on treatments for fatigue that arises from the condition itself. Di>erent treatments may improve symptoms of fatigue in ALS/MND.
These include medicines, which may help people feel more awake, and other treatments, such as exercise. It is unclear whether any of
these treatments are e>ective for improving fatigue in ALS/MND. We reviewed the available studies on the e>ects of treatments for fatigue
in ALS/MND.
Study characteristics
The review included four small studies with a total of 86 participants. Each study investigated a di>erent treatment. These were a drug
treatment (modafinil) compared to placebo, breathing exercises compared to sham (inactive) breathing exercises, exercises with weights
compared to usual care, and magnetic brain stimulation compared to sham rTMS.
Key results and quality of the evidence
We are very uncertain about the e>ects of modafinil, breathing exercises, exercises with weights, or magnetic brain stimulation on fatigue in
people with ALS/MND, as the evidence was very low quality. It was oMen unclear whether studies were adequately designed and performed,
as trial reports oMen lacked details. The results of these small studies were not precise. Three participants stopped taking modafinil because
of side e>ects: headache in two, and chest tightness in one; participants also reported anxiety, nausea, dizziness, and sialorrhoea (inability
to control oral secretions). We need more research on e>ective treatments for fatigue in ALS/MND.
The searches are up to date to September 2017.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Modafinil compared to placebo in ALS/MND
Modafinil compared to placebo in ALS/MND
Patient or population: people with ALS/MND
Setting: Eleanor and Lou Gehrig MND/ALS Research Centre
Intervention: modafinil
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes















Scale from: 9 to 63 (high-
er indicates more fa-
tigue)
follow up: 4 weeks








Adverse events Three adverse events led to discontinuation of modafinil
(2 headache, 1 chest tightness). Anxiety (in 2 people), nau-
sea (in 2), dizziness (in 1), and sialorrhoea (in 1; probably
ALS-related) also occurred with modafinil. Placebo group






The trial reported the number
of adverse events in the treat-
ment group, but not num-
bers of events in the placebo
group or number of people
experiencing adverse events
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect













































































































































1We downgraded the quality of evidence 3 times: once for study limitations and twice for imprecision. The security of blinding in the trial was unclear and the report did not
provide enough information to assess attrition and selective reporting. The trial was small and the CI of the e>ect estimate included appreciable benefit and little or no e>ect.
2We downgraded the quality of evidence 3 times: once for study limitations, twice for imprecision. Reporting of adverse events was incomplete and security of blinding unclear.
The trial was small and the event rate low.
 
 
Summary of findings 2.   Exercise compared to usual care in ALS/MND
Exercise compared to usual care in ALS/MND
Patient or population: people with ALS/MND
Setting: physical therapy service
Intervention: exercise
Comparison: usual care
















Fatigue Severity Scale (FSS)
Scale from: 9 to 63 (higher indi-
cates more fatigue)















None of the people who dis-
continued did so because they
thought the exercise programme
was making their condition
worse. No participants reported
excessive soreness, cramping, or
fatigue.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different













































































































































Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1We downgraded the evidence 3 times to low quality: twice for imprecision as the trial was very small and CI included appreciable benefit and appreciable harm. The third
downgrading was for study limitations as the nature of the intervention prevented participant blinding.
 
 
Summary of findings 3.   Inspiratory muscle training compared to sham intervention in ALS/MND
Inspiratory muscle training compared to sham intervention in ALS/MND
Patient or population: people with ALS/MND
Setting: home-based intervention
Intervention: inspiratory muscle training
Comparison: sham intervention


















Fatigue Severity Scale (FSS)
Scale from: 9 to 63 (higher indicates
more fatigue)
follow up: 4 months
An illustrative
mean FSS score


















*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect













































































































































1The mean FSS score in the control group aMer 4 months was not available from Pinto 2012. The value given here, for illustrative purposes, is the control group mean at 6 months
from Dal Bello Haas 2007.
2We downgraded the quality of evidence 3 times to very low: twice for imprecision and once for study limitations. The trial was very small and CI included appreciable benefit
and little or no e>ect. The nature of the intervention meant that the trainer was aware of the intervention group.
 
 
Summary of findings 4.   Repetitive transcranial magnetic stimulation (rTMS) compared to sham intervention in ALS/MND
Repetitive transcranial magnetic stimulation (rTMS) compared to sham intervention in ALS/MND
Patient or population: people with ALS/MND
Setting: secondary care
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Comparison: sham intervention











No FSS scores were given. The investigators assessed fatigue with the FSS using 2-way analysis of vari-
ance (within-subjects factor time, between-subjects treatment arm). The trial reported a significant
effect for fatigue at the end of the follow-up period. The effect was non-significant following post hoc









RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1We downgraded the quality of evidence 3 times: once for study limitations and twice for imprecision. The risk of bias was unclear as the trial report provided too little detail
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B A C K G R O U N D
Fatigue is a commonly reported symptom in people with
amyotrophic lateral sclerosis/motor neuron disease (ALS/MND)
(Ramirez 2008), with a large proportion of people reporting
'clinically significant' levels of fatigue (McElhiney 2009). Fatigue
in ALS/MND has been defined as "reversible motor weakness
and whole-body tiredness that was predominantly brought on by
muscular exertion and was partially relieved by rest" (Gibbons
2013a). In ALS/MND, fatigue is distinguished from sleepiness
by feelings of weariness or exhaustion that do not necessarily
beget a desire to sleep. This fatigue appears to be experienced
predominantly as general (feelings of whole-body tiredness)
and physical (reversible motor weakness). People with other
neurological diseases, such as multiple sclerosis, describe an
experience of general physical fatigue occurring alongside
cognitive fatigue (reversible reduction in concentration or mental
performance)(Lou 2003; Mills 2008).
In ALS/MND, fatigue can be experienced as a pervasive feeling of
tiredness or lethargy, or as an objective decline in the ability of a
muscle to contract to maximum force (Gibbons 2011; Lou 2012).
The first type of fatigue is ubiquitous in humans, and may have
been experienced by the individual before diagnosis; however,
following development of ALS/MND, the severity of this fatigue
and precipitating factors substantially change. The second type of
fatigue, objective motor fatigue, also known as physical fatigability,
is unique to the disease state and is not normally within a person’s
previous experience. Both types of fatigue have been shown to be
important to people with ALS/MND (Gibbons 2011), and fatigue,
more generally, impacts negatively upon quality of life (Lou 2003).
Evidence for the relationship between fatigue and functional ability
is conflicting. Although some studies have suggested that fatigue
is related to functional capacity (Lo Coco 2012; McElhiney 2009),
others have been unable to support this claim (Gibbons 2011;
Ramirez 2008). Fatigue appears to be related to common nighttime
complaints in ALS/MND, including muscle cramps and nocturia
(Lo Coco 2012). Fatigue is related to psychological distress, social
withdrawal, and reduced quality of life for people with ALS/MND
(Gibbons 2013b; Lou 2003).
Description of the condition
ALS/MND is a progressive, terminal neurodegenerative disease of
unknown aetiology that is currently without a cure. The incidence
of ALS/MND is around 2.16 per 100,000 person-years (Logroscino
2010). At any one time, approximately 5000 people in the United
Kingdom are a>ected (Shaw 1999), and 25,000 in North America
(McGuire 1996).
Rapid progression of the disease causes weakness and muscular
atrophy, impacting upon an individual's ability to carry out
activities of daily living, such as dressing, bathing, and eating.
Problems with speech and swallowing oMen occur as the result
of weakness in bulbar musculature. As the disease progresses,
breathing issues (including nocturnal hypoventilation and reduced
sleep quality) become apparent, and may progress until respiratory
failure occurs (Bourke 2004). Death has been reported in most
people with MND within two to five years following diagnosis,
usually from respiratory failure, caused by respiratory muscle
weakness (Rowland 2001).
Description of the intervention
Currently, no evidence-based treatment is available for fatigue in
people with ALS/MND. Several drugs have been investigated as
treatment for fatigue in this population, including amantadine,
pemoline, and bupropion, although evidence regarding their
e>icacy is lacking (Jackson 2006). Modafinil, a novel wakefulness-
promoting agent that has been approved for the treatment of
excessive sleepiness associated with narcolepsy, may also be an
e>ective treatment for fatigue (Carter 2005; McElhiney 2009; Rabkin
2009).
Dietary supplementation of creatine may increase, or at least
preserve, muscular strength, and reduce levels of fatigue
(Rosenfeld 2008).
Other non-pharmacological therapies may be used to ameliorate
fatigue. Studies have evaluated the potential benefits of supported
treadmill ambulation (Sanjak 2010), muscular exercise (Drory
2001), and repetitive transcranial magnetic stimulation (rTMS) (Guo
2012; Zanette 2008) for this purpose.
How the intervention might work
Pharmacological interventions that stimulate the central nervous
system (CNS) may reduce generalised fatigue for people with
ALS/MND. Modafinil stimulates the release of norepinephrine and
dopamine from synaptic terminals and elevates hypothalamic
levels of histamine (Ishizuka 2008). Creatine, which increases
maximum availability for energy output in anaerobic activities,
may also have a positive e>ect on muscle strength and fatigue
(Ellis 2004; Kley 2013; Rosenfeld 2008). Di>erent treatments may be
e>ective for di>erent forms of fatigue.
Non-pharmacological interventions may focus on light exercise,
including supported or unsupported exercises (e.g. walking), or
resistance training using weights (Bello-Haas 2007).
Why it is important to do this review
Fatigue is prevalent in people with ALS/MND and has a significant
impact on quality of life. Presently, clarity regarding the best
management of fatigue in this population is lacking. This
review is the first systematic review of pharmacological and
non-pharmacological interventions for fatigue in ALS/MND. The
purpose of this review is to identify interventions to reduce primary
fatigue, which is disease related. We will not consider secondary
causes of fatigue, such as malnutrition and chronic respiratory
failure, which have been assessed in other Cochrane systematic
reviews (Katzberg 2011; Radunovic 2017).
O B J E C T I V E S
To assess the e>ects of pharmacological and non-pharmacological
interventions for fatigue in ALS/MND.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised and quasi-randomised controlled trials,
which assessed the e>ectiveness of pharmacological and non-
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pharmacological treatments for fatigue in people with ALS/MND in
this review.
Types of participants
We included studies in which study participants were diagnosed
with possible, probable, or definite ALS/MND, according to
recognised criteria, preferably the El Escorial criteria (Brooks 2000).
Types of interventions
We included all interventions that aimed to reduce fatigue in
people with ALS/MND, and measured it as either a primary
or a secondary objective. These pharmacological or non-
pharmacological treatments could be compared to each other,
placebo, or standard care. Examples of such treatments included
drug treatments (e.g. modafinil) and behavioural interventions.
Types of outcome measures
Primary outcomes
The primary outcome was level of fatigue at the end of the follow-
up period.
Fatigue could be evaluated using any validated patient- or clinician-
administered fatigue questionnaire that measures general fatigue,
including the Modified Fatigue Impact Scale (MFIS) (Fisk 1994) and
the Fatigue Severity Scale (FSS) (Krupp 1989). We also included
questionnaires that measured general fatigue and reversible
muscle weakness, such as the Neurological Fatigue Index–MND
(NFI-MND) (Gibbons 2011).
Secondary outcomes
Secondary outcomes were assessed at the end of the follow-up
period, and could include the following.
1. Sleepiness of participants measured by a validated scale
including the Epworth Sleepiness Scale (ESS) (Johns 1991).
2. Depression measured by a validated scale or by a clinical
diagnostic interview, including the Hospital Anxiety and
Depression Scale (HADS) (Zigmond 1983), or the Beck
Depression Inventory (BDI) (Beck 1988).
3. Quality of life of participants measured by a validated objective
or subjective instrument, including the ALS Specific Quality of
Life-Revised (ALSSQOL-R) (Felgoise 2008), the McGill Quality of
Life Questionnaire (Cohen 1995), or the Short Form-36 Health
Survey (SF-36) (Ware 1992).
4. Functional status of participants measured by a validated scale
such as the ALS Functional Rating Scale-Revised (ALSFRS-R)
(Cedarbaum 1999).
5. Adverse e>ects.
Search methods for identification of studies
Electronic searches
We searched the following databases on 5 September 2017.
• Cochrane Neuromuscular Specialised Register and Cochrane
Central Register of Controlled Trials (CENTRAL) via the Cochrane
Register of Studies (CRS-Web); (searched 5 September 2017)
using the search strategy in Appendix 1
• MEDLINE (1966 to August 2017) using the search strategy in
Appendix 2.
• Embase (1980 to August 2017) using the search strategy in
Appendix 3.
• PsycINFO (1806 to August 2017) using the search strategy in
Appendix 4.
• CINAHL Plus (Cumulative Index to Nursing and Allied Health
Literature Plus; 1937 to August 2017) using the search strategy
in Appendix 5.
• ERIC (1966 to August 2017) using the search strategy in Appendix
6
Searching other resources
We scanned available conference abstracts from International
ALS/MND Symposia for relevant studies. We checked all
references in the identified trials, and contacted trial authors
to identify additional published or unpublished data. We
searched trial registries (US National Institutes of Health trials
registry, ClinicalTrials.gov (clinicaltrials.gov/), and the World
Health Organization International Clinical Trials Registry Platform
(ICTRP; apps.who.int/trialsearch/)) to identify ongoing trials. We
considered trials published in languages other than English to be
eligible for inclusion, following translation.
Data collection and analysis
Selection of studies
Three review authors (CAY, CG, and FP) checked titles and
abstracts identified during the electronic searches. These review
authors obtained the full text of all potentially relevant studies
for independent assessment. All review authors independently
assessed which trials fit the inclusion criteria. We resolved
disagreements about inclusion criteria by discussion and
consensus.
We excluded duplicate reports, and collated multiple reports of the
same study, so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process
in su>icient detail to complete a PRISMA flow diagram and a
'Characteristics of excluded studies' table.
Data extraction and management
Two review authors (CG and FP) independently extracted data onto
a specially designed form; the other two review authors (CAY and
TF) checked the data extraction. One review author entered the
data into the soMware (CG), another (FP) checked the entered data.
Where data allowed, we extracted the following study
characteristics.
1. Methods: study design, total duration of study, details of any
'run-in' period, number of study centres and locations, study
settings, withdrawals, and date of study.
2. Participants: number (N), mean age, age range, gender, severity
of condition, diagnostic criteria, baseline characteristics,
inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of trial
authors.
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Assessment of risk of bias in included studies
Two review authors (CG and FP) independently assessed risk of bias
for each study using the Cochrane 'Risk of bias' tool, as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). All review authors discussed
disagreements related to risk of bias, and reached a consensus. We
assessed risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other sources of bias.
We graded studies as having high, low, or unclear risk of bias in each
of these domains, and provided justifications for these judgements
in the 'Risk of bias' table in Characteristics of included studies.
Measures of treatment e:ect
If su>icient studies had been included, we would have evaluated
treatment e>ects for continuous outcomes using mean di>erences
(MDs), or standardised mean di>erences (SMDs) for results across
studies with outcomes that were conceptually the same, but
measured in di>erent ways. In the event that studies presented
dichotomous data (e.g. responder analyses), we would have used
risk ratios (RRs). We would have calculated 95% confidence
intervals (CIs) for the measures of treatment e>ect.
We would have undertaken meta-analyses only where meaningful,
that is, when treatments, participants, and the underlying clinical
questions were similar enough for pooling to make sense.
Assessment of reporting biases
If we had identified a large number of eligible studies, we would
have analysed a funnel plot to assess the potential existence of
small-study bias.
Data synthesis
We had planned to use the random-e>ects model for the summary
e>ect measure in any meta-analysis. The weights for the studies
would have been be inverse to the variances. The random-e>ects
model incorporates possible between-study variation as well as
within-study di>erences, and so is more conservative. The fixed-
e>ect model assumes that no between-study di>erences exist. Both
models yield very similar results, unless significant between-study
di>erences are noted (heterogeneity).
'Summary of findings' table
We created 'Summary of findings' tables, using fatigue as
the outcome. We used the five GRADE considerations (study
limitations, inconsistency of e>ect, imprecision, indirectness, and
publication bias) to assess the quality of a body of evidence
(studies that contributed data for the outcome). We also included
adverse events. Since we included only RCTs and quasi-RCTs
in this review, we started from an assumption of high-quality
evidence, from which we downgraded the quality to moderate,
low, or very low, based on the extent to which the GRADE
considerations presented a threat to validity. We used methods
and recommendations described in Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2011) and GRADEpro soMware (GRADEpro 2008). We justified all
decisions to downgrade or upgrade the quality of studies using
footnotes, with comments to aid readers' understanding of the
review when necessary.
Subgroup analysis and investigation of heterogeneity
We would have assessed the level of functional impairment,
measured using the ALSFRS-R (Cedarbaum 1999), to identify
heterogeneity of participants. If numbers had allowed, we would
have used this scale to create subgroups of participants to analyse
separately and compare.
Sensitivity analysis
If a study was of doubtful eligibility for the systematic review,
appeared to be an outlier, or had missing data that were impossible
to retrieve, we had intended to compare the results of analyses
with and without the trial. However, there was only one trial for any
comparison.
This review has a published protocol (Gibbons 2014).
R E S U L T S
Description of studies
Our searches identified a total of 243 reports. AMer we removed
duplicates, we had 157, 25 of which were potentially relevant
randomised controlled trials (RCT). The number of references
returned from each database was: Cochrane Neuromuscular
Specialised Register 31, CENTRAL 52, MEDLINE 56, Embase 80,
PsycINFO 3, CINAHL Plus 20, and ERIC 1. We identified one
additional reference from other sources. See Figure 1 for a PRISMA
flow chart illustrating the study selection process.
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The double-blind trial by Rabkin and colleagues aimed to evaluate
the e>ect of modafinil on fatigue in people with probable or definite
ALS by modified El Escorial criteria (Rabkin 2009). They used a
3:1 modafinil:placebo design, in doses up to 300 mg/day for four
weeks, followed by eight weeks of open maintenance treatment.
Measures were collected at baseline, weeks two and four, and
biweekly thereaMer. Primary outcome analyses were conducted at
week four. The primary outcome was fatigue, measured by the FSS.
Secondary outcomes included sleepiness and depression.
Resistance exercise versus usual care
Dal Bello Haas and colleagues conducted a RCT of resistance
exercise for people with clinically definite, probable, or laboratory-
supported amyotrophic lateral sclerosis/motor neuron disease
(ALS/MND) (Dal Bello Haas 2007). Twenty-seven participants were
randomly assigned to either a resistance exercise group (N = 13), or
a usual care group, which consisted of stretching exercises (N = 14).
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease (Review)
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Participants in the resistance exercise group were given stretching
exercises plus an individualised moderate-load and moderate-
intensity resistance exercise programme for upper and lower limbs.
Participants were assessed at baseline, and once monthly for
six months thereaMer. The primary outcome of the study was
change in global function, measured by the Amyotrophic Lateral
Sclerosis Functional Rating Scale (ALSFRS). Secondary outcomes
were health-related quality of life (measured using the Short Form
36 (SF-36) Health Survey), and fatigue (measured using the Fatigue
Severity Scale (FSS)).
Respiratory exercise versus sham intervention
This study evaluated the e>ect of respiratory exercise in people
with definite or probable ALS (Pinto 2012). The intervention was
inspiratory muscular training, consisting of inhaling and exhaling
through a threshold-inspiratory muscle training (IMT) device, which
was a plastic cylinder with a mouthpiece and spring-loaded valve
that could be set to di>erent pressure thresholds. Twenty-six
participants were recruited into the trial; all participants received
an IMT device. The participants were randomised into either an
active intervention group (IMT resistance set at 30% to 40% of
maximal inspiratory pressure (MIP)) or a sham intervention group
(IMT resistance set to the lowest possible load, to remove any
therapeutic e>ect). All participants received instructions to blow
into the tube for 10 minutes twice daily. AMer an initial four-
month intervention period, all participants received the active
intervention for a further four months. The primary outcome
measure was decline in ALSFRS. Other outcomes relevant to
this review were the respiratory subscore of the ALSFRS; fatigue
assessed using the FSS, depression (Hamilton Rating Scale for
Depression (HRSD)), sleepiness (Epworth Daytime Sleepiness Scale
(ESS)), the Functional Independent Measure (FIM), which is an 18-
item ordinal scale of independence, and quality of life (measured
using the EuroQol-5D). Trialists evaluated fatigue during respiratory
training by the Borg scale.
Repetitive transcranial magnetic stimulation (rTMS) versus
sham intervention
Zanette and colleagues conducted a randomised-controlled pilot
study to assess the e>ect of 5-Hz repetitive rTMS on motor
performance, fatigue, and quality of life (QoL) (Zanette 2008). Ten
people with probable or definite ALS attended a two-week period
of either real or sham 5-Hz rTMS. Participants were examined at
baseline, aMer the first day of treatment, and aMer two weeks
of rTMS treatment. Outcomes relevant to this review included
ALSFRSr, FSS, and quality of life, measured using the MOS 36-Item
Short Form Health Survey (SF-36).
Excluded studies
We excluded 13 studies because (i) they were not RCTs (Carter
2005), (ii) did not assess fatigue as an end point (Drory 2001;
Dupuis 2012; Goonetilleke 1995; Gordon 2007), or (iii) did not
include a validated, patient-reported measure for fatigue (Bertorini
2011; Cudkowitz 2003; Desnuelle 2001; Lange 2006; Mazzini 2001;
Rosenfeld 2009; Silva 2009; Steele 2004).
Risk of bias in included studies
Figure 2 shows the review authors' 'Risk of bias' assessments using
the Cochrane 'Risk of bias' tool.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias domain for each included study.
 
The risk of bias in the included studies was generally unclear, as
all study reports tended to omit important information concerning
risk of bias. Eighteen of the 28 risk of bias domains were judged
to be unclear. However, where this information was reported, the
majority (7 out of 10) of the judgements were of a low risk of bias.
Two cases in which risk of bias was judged to be high, related to
blinding of participants and personnel. In one study the patients
received training for the intervention and follow-up calls to ensure
compliance from a physician who was aware of group allocation
(Pinto 2012). In the other study, the participants and personnel
were unblinded, however the outcome assessor was blinded and
participants were asked not to reveal their assignment(Dal Bello
Haas 2007). Although the dropout rate in this study was high,
reasons for withdrawal were unrelated to the intervention and we
considered the risk of attrition bias to be low. We assessed the risk
of other bias as high for another study in which the dropout rate was
high in the intervention arm (16%) (Rabkin 2009).
E:ects of interventions
See: Summary of findings for the main comparison Modafinil
compared to placebo in ALS/MND; Summary of findings 2 Exercise
compared to usual care in ALS/MND; Summary of findings 3
Inspiratory muscle training compared to sham intervention in ALS/
MND; Summary of findings 4 Repetitive transcranial magnetic
stimulation (rTMS) compared to sham intervention in ALS/MND
Modafinil versus placebo
Reported in Rabkin 2009. Of the 32 (25 intervention, 7 control)
people randomised, 28 completed the four-week double-blind
phase, with all four dropouts coming from the intervention group.
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Primary outcome
Level of fatigue at the end of the follow-up period
The possible range in Fatigue Severity Scale (FSS, total) is from 9
to 63, with higher scores indicating more fatigue or more fatigue-
related problems.
Level of fatigue was assessed using the FSS in an intention-to-treat
(ITT) analysis. At the end of the follow-up period, the mean score in
the modafinil group (adjusted mean (SE) 32 (3.6)) was lower than in
the placebo group (adjusted mean (SE) 43 (5.0)) (MD -11.00, 95% CI
-23.08 to 1.08; P = 0.066; Analysis 1.1).
We downgraded the quality of evidence to very low (-3): once for
study limitations and twice for imprecision. The security of blinding
in the trial was unclear and the report did not provide enough
information to assess attrition and selective reporting. The trial was
small and the 95% CI of the e>ect estimate included appreciable




The range of possible Epworth Sleepiness Scale (ESS) scores is from
0 to 24, with higher scores indicating more sleepiness.
Sleepiness was assessed using the ESS in an ITT analysis at the end
of the follow-up period. There was little or no di>erence in adjusted
mean scores (SE) for sleepiness between the modafinil group (5
(0.6)) and the placebo group (7 (1.1)) (MD -2.00, 95% CI -4.46 to
0.46; Analysis 1.1). The result was imprecise; 95% CI included both
a potentially clinically relevant e>ect and no e>ect.
Depression
Scores in the Beck Depression Inventory-II (BDI-II) range from 0
to 63, with higher scores indicating greater severity of depressive
symptoms.
The BDI-II was used to assess depression at the end of the follow-up
period in an ITT analysis. There was no di>erence in adjusted mean
score between the modafinil group (adjusted mean (SE) 9 (1.0)) and
the placebo group (adjusted mean (SE) 9 (2.0)) (MD 0.00 95% CI -4.38




Not assessed using the ALS Functional Rating Scale (ALSFRS) or
revised ALSFRS (ALSFRS-R).
Statistically significant improvements were demonstrated in the
Clinical Global Impression Score (Chi2 = 8.887, degrees of freedom
(df) = 1; P = 0.003). Only 1/7 participants (14%) in the placebo group
reported that they were much or very much improved, compared
to 19/25 participants (75%) in the intervention group. All data were
taken from the published report.
Adverse e:ects
Three participants in the modafinil group dropped out due to
side e>ects (two with headache, one with tightness in chest); a
fourth for lack of e>ect and burden of travel). A participant in
the placebo group discontinued modafinil because of 'agitation'
during a subsequent open-label phase of the study. Anxiety (in
2 participants), nausea (in 1), dizziness (in 1), and sialorrhoea (in
1, probably ALS-related) also occurred with treatment. Numerical
analysis was not possible, as the number of participants with
adverse events was not reported.
We downgraded the quality of evidence to very low (-3): once for
study limitations and twice for imprecision. Reporting of adverse
events was incomplete and security of blinding was unclear. The
trial was small and the event rate low. See Summary of findings for
the main comparison.
Resistance exercise versus usual care
Reported in Dal Bello Haas 2007. The study randomly assigned 27
people to receive resistance exercise (N = 13) or usual care (N = 14).
Five participants from the intervention group and four participants
from the control group dropped out for reasons unrelated to the
tolerability of the intervention. Data represent an available case
analysis of the remaining eight participants in the intervention
group and 10 participants in the usual care group.
Primary outcome
Level of fatigue at the end of the follow-up period
Dal Bello Haas 2007 measured fatigue using the FSS at six months.
The possible range in FSS (total) is from 9 to 63. Higher scores
indicate more fatigue or more fatigue-related problems.
The intervention had little e>ect on fatigue, as scores on the FSS
were 42.9 ± 8.7 in the intervention group (N = 8) and 42.7 ± 15.2 in
the usual care group (N = 10) at six-month follow-up (MD 0.20, 95%
CI -10.98 to 11.38; Analysis 2.3).
We downgraded the quality of evidence to very low (-3): once for
study limitations (lack of blinding) and twice for imprecision, as
the 95% CI included appreciable benefit and appreciable harm. See





Mental health was assessed using the Short Form-36 Health Survey
(SF-36) Mental Health subscale, with a range of possible scores from
0 to 100, with a higher score indicating better health.
SF-36 Mental Health subscale scores (mean ± SD) showed no clear
di>erence between the resistance exercise and usual care group at
6-month follow-up: 22.3 ± 4.0 in the resistance exercise group (N =
8) and 24.0 ± 4.2 in the usual care group (N = 10) (MD -1.70, 95% CI
-5.50 to 2.10; Analysis 2.3).
Quality of life
Quality of life was assessed using the eight subscales of the SF-36,
including mental health, reported above. All of the SF-36 scales
have scores that range from 0 to 100, with higher scores indicating
a more favourable state.
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The study reported less impairment in physical function in the
resistance exercise group (N = 10) than in the usual care group (N =
8) at six-months follow-up: intervention group (mean ± SD) 21.1 ±
7.6 versus usual care group 14.0 ± 3.9 (MD 7.10, 95% CI 1.31 to 12.89;
Analysis 2.3).
The trial found little or no di>erences between the resistance
exercise (N = 10) and usual care group (N = 8) on any other
SF-36 subscale (Analysis 2.3): Physical Role subscale (mean ± SD):
resistance exercise group 5.1 ± 1.0, usual care 4.9 ± 1.7 (MD 0.20,
95% CI -1.06 to 1.46}; Pain subscale: resistance exercise 10.2 ± 2.3,
usual care 10.3 ± 1.7 (MD -0.10, 95% CI -2.01 to 1.81); General Health
subscale: resistance exercise 16.4 ± 3.4, usual care 16.0 ± 6.6 (MD
0.40, 95% CI -4.32 to 5.12); Vitality subscale: resistance exercise 16.4
± 3.4, usual care 14.8 ± 4.1 (MD 1.60, 95% CI -1.87 to 5.07); Social
Function subscale: resistance exercise 8.4 ± 1.5, usual care 7.7 ±
2.1 (MD 0.7, 95% CI -0.97 to 2.37); and Emotional Role subscale:
resistance exercise group 5.3 ± 0.9, usual care 4.7 ± 1.4 (MD 0.60, 95%
CI -0.47 to 1.67).
Functional status
The study demonstrated less decline in physical function overall in
the resistance exercise group: resistance exercise group (mean ± SD)
33.8 ± 4.7, usual care 28.1 ± 4.8 (MD 5.7, 95% CI 1.29 to 10.11) and in
the lower extremities: intervention group 18.8 ± 4, usual care 13.5 ±
3.4 (MD 5.50, 95% CI 1.82 to 8.78) (Analysis 2.3).
Adverse e:ects
None of the participants who discontinued did so because they
thought the exercise programme itself was making their condition
worse. No participants reported excessive soreness, cramping, or
fatigue with either exercise protocol.
We downgraded the quality of evidence to very low (-3): once for
study limitations (lack of blinding) and twice for imprecision, as
the 95% CI included appreciable benefit and appreciable harm. See
Summary of findings 2.
Respiratory exercise versus sham intervention
Pinto 2012 randomised 26 participants to receive resistance
exercise (N = 13) or sham intervention (N = 13), of whom 12 in
each group were evaluable. Due to the delayed-start design for
the control group, we only considered the results of the first four
months of the intervention, during which we could compare the
active and sham groups.
Primary outcome
Level of fatigue at the end of the follow-up period
Fatigue was assessed using the FSS, with a possible total range from
9 to 63. Higher scores indicate more fatigue or more fatigue-related
problems.
At the end of the first follow-up period the intervention group
showed less fatigue than the sham intervention group (MD -9.65,
95% CI -22.04 to 2.73; N = 24; Analysis 3.1).
We downgraded the quality of evidence to very low (-3): twice for
imprecision and once for study limitations. The trial was very small
and 95% CI included appreciable benefit and little or no e>ect. The
nature of the intervention meant that the trainer was aware of the
intervention group. See Summary of findings 3.
Secondary outcomes
Sleepiness
The range of possible ESS scores is from 0 to 24. Higher scores
indicate more sleepiness.
We found no clear di>erences between groups in mean scores on
the ESS questionnaire at the end of the first follow-up period (MD
0.31, 95% CI -3.48 to 4.10; N = 24; Analysis 3.1).
Depression
The range of possible Hamilton Depression Rating Scale (HDRS, or
Ham-D) scores, which was used to measure depression, is from 0 to
63. Higher scores indicate greater severity of depression.
Depression was lower in the respiratory exercise group than the
usual care group at the end of the first follow-up period (MD 1.77,
95% CI 0.02 to 3.52; N = 24; Analysis 3.1).
Quality of life
Quality of life was assessed using the EuroQol - 5 dimension
instrument (EQ-5D), with a range in scores from 1 to 25. Higher
scores indicate lower health-related quality of life.
There was no significant di>erence in quality of life at the end of the
first follow-up period between the resistance exercise and the usual
care groups (MD 0.77, 95% CI -17.10 to 18.63; N = 24; Analysis 3.1).
Functional status
Functional status was assessed with the ALSFRS, administered by a
blinded evaluator. There was no di>erence between groups in mean
scores for the overall scale at the end of the first follow-up (MD 0.85,
95% CI -2.16 to 3.85; N = 24), the ALSFRS-b bulbar subscale (MD
-0.39, 95% CI -1.38 to 0.61; N = 24), or the respiratory subscale (MD
0.08, 95% CI -0.25 to 0.41; N = 24; Analysis 3.1).
Adverse e:ects
There were no adverse e>ects reported.
We downgraded the quality of evidence for this outcome to very
low (-3): twice for imprecision and once for study limitations. The
trial was very small. The nature of the intervention meant that
the trainer was aware of the intervention group. See Summary of
findings 3.
Repetitive transcranial magnetic stimulation (rTMS) versus
sham intervention
Zanette 2008 randomised 10 participants to receive rTMS (N = 5) or
the sham intervention (N = 5).
Primary outcome
Level of fatigue at the end of the follow-up period
Fatigue was measured using the FSS, and assessed using two-
way repeated measures analysis of variance (ANOVA; the within-
subjects factor was time and the between-subjects factor was
treatment arm). The paper reported a significant e>ect from rTMS
for fatigue at the end of the two-week follow-up period (F[2,16] = 4.0;
P = 0.04; Analysis 4.1). The e>ect was non-significant following post
hoc Bonferroni adjustments (data not reported). The paper did not
provide mean scores, SDs, or CIs.
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We downgraded the quality of evidence to very low (-3): once for
study limitations and twice for imprecision. The trial involved 10
people. The risk of bias was unclear, as the trial report provided too







Quality of life was assessed using the global score from the SF-36,
a method for which there is no evidence of psychometric validity
(Ware 1992).
Functional status
The ALSFRSr was used to assess functional status at the end of the
follow-up period, using complete data. ANOVA tests demonstrated
no significant interaction between time and treatment (F[2,16] = 2.7;
P > 0.05; Analysis 4.1). The paper did not report mean scores, SDs,
or CIs.
Adverse e:ects
No adverse events were reported.
D I S C U S S I O N
Summary of main results
We included four studies (86 participants) that met the
eligibility criteria in this review. They evaluated pharmacological
interventions (modafinil) (Rabkin 2009) and non-pharmacological
interventions, including resistance exercise (Dal Bello Haas 2007),
respiratory exercise (Pinto 2012), and repetitive transcranial
magnetic stimulation (rTMS) (Zanette 2008) We are very uncertain
about the e>ects of these interventions on fatigue in ALS, as the
quality of evidence was too low to rule out any negative e>ect or
establish clinical benefit.
Rabkin 2009 (32 participants) conducted an ITT analysis that
showed improved fatigue at the end of a brief double-blind phase
for the modafinil group, although the 95% CI were wide, and
allowed for the possibility of no e>ect.
Resistance exercise had little e>ect on fatigue in Dal Bello Haas 2007
(27 participants).
In Pinto 2012 (26 participants), there was reduced fatigue in the
respiratory exercise group over the sham intervention group, but
the results were imprecise and 95% CI were consistent with both
a large e>ect and none. No clear di>erences between groups
were reported for sleepiness, quality of life, or functional status,
but there was small reduction of depressive symptoms in the
respiratory exercise group.
Zanette 2008 (10 participants) reported that improvements
in fatigue in the rTMS group showed a "trend towards"
statistical significance before post hoc tests corrected for multiple
comparisons. These e>ects were short-lived, and aMer two weeks
with no treatment, the trialists reported that there was no
clear di>erence between the two groups on any of the reported
outcomes.
In the modafinil study, three participants dropped out from the
intervention arm due to side e>ects including headache and
headache with chest tightness. The trial authors noted that similar
adverse events were not reported in another RCT they had run
with over 100 people with HIV/AIDS (Rabkin 2009). Similarly, an
open-label trial of modafinil for ALS/MND reported that the drug
was well tolerated in both the 200 mg and 400 mg groups (Carter
2005). Rabkin and colleagues also ran a completer's analysis, in
which the positive e>ect of modafinil in alleviating fatigue was
more pronounced, with e>ect sizes significant at the 5% level for
fatigue, sleepiness, energy, and stamina (Rabkin 2009).
No adverse events were reported in any of the non-
pharmacological trials.
Overall completeness and applicability of evidence
We identified four studies. Each evaluated di>erent interventions
which, at best, reported weak or transient beneficial e>ects.
The heterogeneity in the assessed interventions precluded meta-
analysis of the disparate outcomes. Therefore, no reliable
information was available to assess whether di>erent treatments
for fatigue may be beneficial or harmful for people with ALS/MND.
This review highlights a clear need to commit high-quality evidence
to the corpus of literature relating to treatment for fatigue in people
with ALS/MND.
Quality of the evidence
We assessed the overall risk of bias from low to unclear for two of
the four studies. We found issues relating to blinding of participants
or personnel in two of the trials. In Pinto 2012, the trainer was aware
of the group allocation and in Dal Bello Haas 2007, the participants
were unblinded due to the nature of the intervention. Though
they were asked not to reveal their allocation to the assessors, no
formal evaluation took place to confirm that assessors remained
unblinded throughout the trial period. High dropout introduced a
high risk of bias for the study by Rabkin and colleagues of modafinil
versus placebo (Rabkin 2009). It is notable that more than half of the
risk of bias domains could not be ascertained from the published
reports. All results lacked precision and were based on findings
from single small studies. There is an additional risk that we were
unable to identify all relevant controlled research studies, due to
publication bias.
Potential biases in the review process
We followed the Cochrane Neuromuscular search strategies, which
include a search of the Cochrane Neuromuscular Specialised
Register, which is updated weekly to monthly from a range of
databases. Therefore, it is unlikely that studies have been missed,
although it is possible that studies that have not been published
could be missing. Should any further studies be identified, we will
include them in future updates of the review. We followed the
recommended Cochrane review process to reduce potential biases,
which included having at least two review authors independently
assess identified studies, extract data, and evaluate risk of bias.
The small size of included studies means that estimates of adverse
event rate frequency are unlikely to be accurate, particularly for rare
events.
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Agreements and disagreements with other studies or
reviews
To our knowledge, there are no other systematic reviews on this
topic for people with ALS/MND.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is very limited and low-quality evidence from randomised
controlled trials (RCTs) about treatment to reduce fatigue in
amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).
Therefore, it is uncertain whether modafinil, breathing exercises,
resistance exercise, or repetitive transcranial magnetic stimulation
(rTMS) are of benefit.
Implications for research
Despite the prevalence of fatigue in ALS/MND, we lack high-quality
RCTs that evaluate interventions to improve this disabling, but
potentially treatable symptom. There is a need for considerable
further work to identify an e>ective treatment for fatigue for
people with ALS/MND. Three studies demonstrated very low quality
evidence of benefit for modafinil, inspiratory muscle training,
and rTMS, which may merit further investigation. Unfortunately,
the positive e>ects of rTMS were short lived, and no longer
detected two weeks aMer treatment cessation. Although the e>ect
of modafinil and respiratory exercise is very uncertain, as the
quality of the evidence is very low, they appear to have the greatest
potential as an e>ective treatment for fatigue in ALS/MND.
A C K N O W L E D G E M E N T S
The Methods section includes sections of standard text provided
by Cochrane Neuromuscular. Editorial assistance was provided by
Ruth Brassington.
The search strategy was developed by the Cochrane
Neuromuscular Information Specialist, Angela Gunn, in
collaboration with the review authors.
This project was supported by the National Institute for Health
Research (NIHR) via Cochrane Infrastructure funding to Cochrane
Neuromuscular. The views and opinions expressed herein are those
of the review authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, National Health Service,
or the Department of Health. Cochrane Neuromuscular is also
supported by the Motor Neurone Disease Assocation and the MRC
Centre for Neuromuscular Diseases.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised, placebo-controlled trial
Participants 27 people with a diagnosis of clinically definite, probable, or laboratory-supported ALS, FVC of 90% or
greater, and an ALSFRS score of 30 or greater.
Mean age in years (SD): resistance exercise 56 (7); control 51 (7)
Dal Bello Haas 2007 
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Gender (% female): resistance exercise 4 (30.8%); control 7 (50%)
Mean time since diagnosis in months (SD): resistance exercise 20 (12); control 15 (13)
Interventions Intervention (N = 13)
Moderate-load and moderate-intensity resistance exercise programme and stretching for upper and
lower extremities.
Intervention participants received a personalised 'moderate intensity resistance exercise programme'
by an unblinded research physical therapist. The programmes were developed according to individual
tolerance and limitations.
Control (N = 14)
Stretching exercises for upper and lower extremities only.
Outcomes Primary
Change in global function measured on the ALSFRS at 6 months
Secondary
Fatigue, measured on the FSS
Quality of life, measured on SF-36
Funding Funded by the ALS Association (US)
Conflicts of interest The authors report no conflicts of interest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










High risk Participants not blinded. In addition, the trial authors reported that "[t]he
physical therapists who initially prescribed the exercise programs were un-
blinded to group assignment and were responsible for collecting the logs,
making the telephone contacts, interviewing subjects about exercise side ef-
fects and compliance, and revising the exercise program."
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk 4 usual care participants (40%) and five resistance participants (62.5%) did not
complete the study (P = 0.70). Two participants from each arm who dropped
out were taking riluzole. No participants who discontinued did so because




Low risk All outcomes reported in ClinicialTrials.gov registration
Other bias Low risk No other biases apparent
Dal Bello Haas 2007  (Continued)
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Methods RCT with delayed-start design
Participants 26 people with ALS/MND with normal respiratory function.
Mean age in years (SD): intervention 57 (9); control 56 (8)
Gender (% female): intervention 6 (46.1%); control 2 (15.4%)
Mean time since diagnosis in months (SD): intervention 11 (5); control 12 (6)
Interventions Respiratory exercise using a inspiratory muscular training (IMT) device. All participants instructed to
use the IMT twice daily; each session 10 minutes
Intervention (N = 13)
In the intervention groups the resistance was set to between 30% to 40% of maximum inspiratory pres-
sure (MIP). Participants started the exercise programme at entry and were followed for 8 months.
Control (N = 13)
Sham exercise programme. In the sham intervention group the resistance in the IMT was set to the low-
est possible level. Participants followed a placebo exercise programme at entry, then the active exer-
cise programme for 4 months.
Outcomes Primary




Fatigue, measured on the FSS
Depression, measured on the Hamilton Rating Scale for Depression
Sleepiness, measured on the ESS
Functional Independence, measured on Functional Independence Measure
Quality of life, measured on EuroQoL-5D
Funding Fundacão para a Ciência e a Tecnologia
Conflicts of interest The authors report no conflicts of interest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants independently randomised in blocks of 6
Allocation concealment
(selection bias)
Unclear risk Not discussed
Pinto 2012 
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High risk Trainer aware of participants group assignment
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk For one analysis, incomplete data imputed as 25% of the lower percentile val-
ue observed in the remaining participants of the same group
Selective reporting (re-
porting bias)
Unclear risk No protocol




Methods RCT with 3:1 (intervention:placebo) randomisation
Participants 32 participants with probable or definite ALS by modified El Escorial criteria, FVC ≥ 50% and able to
communicate verbally or with an assistive device.
Mean age in years (SD): modafinil 59 (13); placebo 56 (5)
Gender (% female): modafinil 11 (44%); placebo 3 (43%)
Mean time since diagnosis in months (SD): modafinil 16 (18); placebo 29 (33)
Interventions Intervention (N = 25)
Modafinil in doses beginning with 100 mg/day and increasing in the event of no response to 300 mg/
day for four weeks
Control (N = 7)
Placebo
Outcomes Primary





Conflicts of interest The authors report no conflicts of interest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Rabkin 2009 
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Random sequence genera-
tion (selection bias)









Unclear risk Blinding was maintained and assessed for both doctor and participants, but
"blinding was questionable since participants knew there was a 3:1 chance of
getting modafinil versus placebo"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 16% dropout, 9% due to adverse events. However, there were complete data
for the outcomes of interest in this review.
Selective reporting (re-
porting bias)
Unclear risk No protocol or prespecified outcomes





Participants 10 people with probable or definite ALS/MND randomised.
Mean age in years (SD): intervention 59(9); control 60(9)
Gender (% female): intervention 1 (20%); control 3 (60%)
Mean time since diagnosis in months (SD): intervention 11 (3); control 12 (4).
Interventions Intervention (N = 5)
Daily repetitive transcranial magnetic stimulation (5Hz) on upper- and lower-limb cortical areas
Control (N = 5)
Sham stimulation using a specific sham coil that provided no cortical stimulation but did produce simi-
lar auditory and scalp sensations
2 weeks' treatment
Outcomes Functional status, measured on the ALSFRS-R
Fatigue, measured on the FSS
Medical Research Council (MRC) strength score
Maximum voluntary isometric contraction (MVIC) for upper and lower limbs
Outcomes measured 2 weeks after the end of treatment
Funding Not reported
Conflicts of interest Not reported
Zanette 2008 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Use of sham treatment suggests that participants were blinded; but no explicit
mention of blinding made
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Four week assessments available for all randomised participants
Selective reporting (re-
porting bias)
Unclear risk No protocol or prespecified outcomes
Other bias Low risk No other biases apparent
Zanette 2008  (Continued)
ALS: amyotrophic lateral sclerosis; ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; ESS: Epworth Sleepiness Scale; FSS:
Fatigue Severity Scale; FVC: forced vital capacity; SD: standard deviation; SF-36: Short Form 36 Health Survey
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bertorini 2011 No validated, patient-reported fatigue outcome (study used VAS for fatigue). Double-blind cross-
over trial to assess tolerability of 3-4 diaminopyridine (3,4-DAP)
Carter 2005 Non-randomised study. Open-label trial of modafinil. 2-week trial of 200 mg or 400 mg doses. Sig-
nificant reductions in fatigue (FSS) and sleepiness (ESS) evident after 2 weeks
Cudkowitz 2003 No validated, patient-reported fatigue outcome (study used maximum voluntary isometric con-
traction). RCT of topiramate to slow disease progression
Desnuelle 2001 No validated, patient-reported fatigue outcome (study used VAS for fatigue). Double-blind trial to
assess efficacy of alpha-tocopherol (vitamin E) to treat ALS/MND
Drory 2001 Fatigue not assessed as primary or secondary end point
Dupuis 2012 Fatigue not assessed as primary or secondary end point
Goonetilleke 1995 Fatigue not assessed as primary or secondary end point
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Study Reason for exclusion
Gordon 2007 Fatigue not assessed as primary or secondary end point
Lange 2006 Fatigue assessed using individual items from a validated scale, not the validated scale itself
Mazzini 2001 Fatigue not assessed using validated, patient-reported outcome measure
Rosenfeld 2009 Fatigue not assessed using validated, patient-reported outcome measure
Silva 2009 Fatigue not assessed using validated, patient-reported outcome measure
Steele 2004 Fatigue not assessed using validated, patient-reported outcome measure




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Modafinil versus placebo





Statistical method Effect size
1 Efficacy outcomes (all at 4
weeks)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Fatigue (FSS) 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Sleepiness 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Depression 1   Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Modafinil versus placebo, Outcome 1 E:icacy outcomes (all at 4 weeks).
Study or subgroup Modafinil Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
1.1.1 Fatigue (FSS)  
Rabkin 2009 25 32 (18) 7 43 (13.2) -11[-23.08,1.08]
   
1.1.2 Sleepiness  
Rabkin 2009 25 5 (3) 7 7 (2.9) -2[-4.46,0.46]
   
1.1.3 Depression  
Rabkin 2009 25 9 (5) 7 9 (5.3) 0[-4.38,4.38]
Favours modafinil 5025-50 -25 0 Favours control
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Comparison 2.   Resistance exercise versus usual care





Statistical method Effect size
1 Fatigue (at 6 months) 1   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
1.1 Fatigue (FSS) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
2 Functional status (at 6 months) 1   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
2.1 Functional status (ALSFRS total score) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
2.2 Functional status (ALFRS lower extremi-
ty)
1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3 Quality of life (at 6 months) 1   Mean Difference (IV, Fixed, 95%
CI)
Totals not selected
3.1 Mental health (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.2 Physical function (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.3 Physical role (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.4 Pain (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.5 General health (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.6 Vitality (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]
3.7 Social function (SF-36) 1   Mean Difference (IV, Fixed, 95%
CI)
0.0 [0.0, 0.0]





Analysis 2.1.   Comparison 2 Resistance exercise versus usual care, Outcome 1 Fatigue (at 6 months).
Study or subgroup Exercise Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.1.1 Fatigue (FSS)  
Dal Bello Haas 2007 8 42.9 (8.7) 10 42.7 (15.2) 0.2[-10.98,11.38]
Favours usual care 2010-20 -10 0 Favours exercise
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Analysis 2.2.   Comparison 2 Resistance exercise versus usual care, Outcome 2 Functional status (at 6 months).
Study or subgroup Exercise Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.2.1 Functional status (ALSFRS total score)  
Dal Bello Haas 2007 8 33.8 (4.7) 10 28.1 (4.8) 5.7[1.29,10.11]
   
2.2.2 Functional status (ALFRS lower extremity)  
Dal Bello Haas 2007 8 18.8 (4) 10 13.5 (3.4) 5.3[1.82,8.78]
Favours usual care 105-10 -5 0 Favours exercise
 
 
Analysis 2.3.   Comparison 2 Resistance exercise versus usual care, Outcome 3 Quality of life (at 6 months).
Study or subgroup Exercise Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
2.3.1 Mental health (SF-36)  
Dal Bello Haas 2007 8 22.3 (4) 10 24 (4.2) -1.7[-5.5,2.1]
   
2.3.2 Physical function (SF-36)  
Dal Bello Haas 2007 8 21.1 (7.6) 10 14 (3.9) 7.1[1.31,12.89]
   
2.3.3 Physical role (SF-36)  
Dal Bello Haas 2007 8 5.1 (1) 10 4.9 (1.7) 0.2[-1.06,1.46]
   
2.3.4 Pain (SF-36)  
Dal Bello Haas 2007 8 10.2 (2.3) 10 10.3 (1.7) -0.1[-2.01,1.81]
   
2.3.5 General health (SF-36)  
Dal Bello Haas 2007 8 16.4 (3.4) 10 16 (6.6) 0.4[-4.32,5.12]
   
2.3.6 Vitality (SF-36)  
Dal Bello Haas 2007 8 16.4 (3.4) 10 14.8 (4.1) 1.6[-1.87,5.07]
   
2.3.7 Social function (SF-36)  
Dal Bello Haas 2007 8 8.4 (1.5) 10 7.7 (2.1) 0.7[-0.97,2.37]
   
2.3.8 Emotional role (SF-36)  
Dal Bello Haas 2007 8 5.3 (0.9) 10 4.7 (1.4) 0.6[-0.47,1.67]
Favours usual care 2010-20 -10 0 Favours exercise
 
 
Comparison 3.   Respiratory exercise versus sham intervention





Statistical method Effect size
1 Efficacy outcomes (all at 4 months)     Other data No numeric data
1.1 Fatigue (FSS)     Other data No numeric data
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Statistical method Effect size
1.2 Sleepiness     Other data No numeric data
1.3 Depression     Other data No numeric data
1.4 Quality of life     Other data No numeric data
1.5 Functional status     Other data No numeric data
1.6 Functional status (ALSFRS-bulbar)     Other data No numeric data
1.7 Functional status (ALSFRS-respirato-
ry)
    Other data No numeric data
 
 
Analysis 3.1.   Comparison 3 Respiratory exercise versus sham
intervention, Outcome 1 E:icacy outcomes (all at 4 months).
Efficacy outcomes (all at 4 months)
Study Respiratory exercise N Sham intervention N MD, 95% CI
Fatigue (FSS)
Pinto 2012 12 12 -9.654, 95% CI -22.037 to 2.729
Sleepiness
Pinto 2012 12 12 0.308, 95% CI -3.48 to 4.096
Depression
Pinto 2012 12 12 1.769, 95% CI 0.018 to 3.52
Quality of life
Pinto 2012 12 12 0.769, 95% CI -17.093 to 18.631
Functional status
Pinto 2012 12 12 0.846, 95% CI -2.157 to 3.849
Functional status (ALSFRS-bulbar)
Pinto 2012 12 12 -0.385, 95% CI -1.378, to 0.609
Functional status (ALSFRS-respiratory)
Pinto 2012 12 12 0.077, 95% CI -0.254 to 0.407
 
 
Comparison 4.   Repetitive transcranial magnetic stimulation (rTMS) versus sham intervention





Statistical method Effect size
1 Efficacy outcomes (all at 2 weeks)     Other data No numeric data
1.1 Fatigue (FSS)     Other data No numeric data
1.2 Functional status     Other data No numeric data
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Analysis 4.1.   Comparison 4 Repetitive transcranial magnetic stimulation
(rTMS) versus sham intervention, Outcome 1 E:icacy outcomes (all at 2 weeks).
Efficacy outcomes (all at 2 weeks)
Study Number of participants Analysis of variance (time x treatment arm
Fatigue (FSS)
Zanette 2008 10 (5 rTMS, 5 sham intervention) F[2,16] = 4.0; P = 0.04
Functional status
Zanette 2008 10 (5 rTMS, 5 sham intervention) F[2,16] = 2.7; P > 0.05
 
 
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register and Cochrane Central Register of Controlled Trials
(CENTRAL via CRS-W) search strategy
#1 MeSH DESCRIPTOR Motor Neuron Disease Explode All AND CENTRAL:TARGET
#2 "motor neuron disease*" or "motor neurone disease*" AND CENTRAL:TARGET
#3 "motoneuron disease*" or "motoneurone disease*" AND CENTRAL:TARGET
#4 "motorneuron disease*" or "motorneurone disease*" AND CENTRAL:TARGET
#5 "charcot disease" AND CENTRAL:TARGET
#6 "amyotrophic lateral sclerosis" AND CENTRAL:TARGET
#7 als:ti or als:ab or nmd:ti or mnd:ab AND CENTRAL:TARGET
#8 #1 or #2 or #5 or #6 or #7 AND CENTRAL:TARGET
#9 fatigue or tired* or weariness or weary or exhaust* or lacklustre AND CENTRAL:TARGET
#10 astheni* or lethargic or languidness or languor or lassitude or listlessness AND CENTRAL:TARGET
#11 (lack or loss or lost) near2 (energy or vigour or vigour) AND CENTRAL:TARGET
#12 #9 or #10 or #11 AND CENTRAL:TARGET
#13 #8 and #12 AND CENTRAL:TARGET
#14 MeSH DESCRIPTOR Exercise Therapy Explode All AND CENTRAL:TARGET
#15 MeSH DESCRIPTOR Physical Therapy Modalities Explode All AND CENTRAL:TARGET
#16 rehabilitation or exercise or train or activity or physical or strength or sports AND CENTRAL:TARGET
#17 isometric or isotonic or isokinetic or endurance or kinesiotherap* AND CENTRAL:TARGET
#18 "relaxation therapy" or "behavior therapy" or "behaviour therapy" or "orthotic devices" AND CENTRAL:TARGET
#19 exercise near2 (grading or pacing) AND CENTRAL:TARGET
#20 MeSH DESCRIPTOR Drug Therapy Explode All AND CENTRAL:TARGET
#21 "cognitive therapy" AND CENTRAL:TARGET
#22 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 AND CENTRAL:TARGET
#23 #13 and #22 AND CENTRAL:TARGET
#24 #13 and #22 AND CENTRAL:TARGET
#25 (#13 and #22) AND (INREGISTER)
#26 181:zsen AND INREGISTER AND ISINCENTRAL
#27 181:zsen AND INSEGMENT AND ISINCENTRAL
#28 #26 OR #27
#29 #24 not #28
#3 "motoneuron disease*" or "motoneurone disease*" AND CENTRAL:TARGET
#30 #25 not #26
#31 #29 OR #30
Appendix 2. MEDLINE Ovid SP search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Ovid MEDLINE(R) 1946 to August Week 4 2017
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (476988)
2 controlled clinical trial.pt. (96146)
3 randomized.ab. (417587)
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4 placebo.ab. (194961)





10 exp animals/ not humans.sh. (4531946)
11 9 not 10 (3650505)
12 exp Motor Neuron Disease/ (24501)
13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (8212)
14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (179)
15 charcot disease.tw. (21)
16 amyotrophic lateral sclerosis.tw. (19305)
17 or/12-16 (32403)
18 Fatigue/ or fatigue.mp. (92934)
19 (tired$ or weariness or weary or exhaust$ or lacklustre or astheni$ or lethargic or languidness or languor or lassitude or listlessness).mp.
(60396)
20 ((lack or loss or lost) adj2 (energy or vigour or vigour)).mp. (6665)
21 18 or 19 or 20 (154071)
22 17 and 21 (335)
23 Fatigue/dh, dt, th [Diet Therapy, Drug Therapy, Therapy] (2687)
24 exp Exercise Therapy/ (42299)
25 exp Physical Therapy Modalities/ (135665)
26 rehabilitation.mp. or Rehabilitation/ (161213)
27 (exercise or train or activity or physical or exercise or strength or sports or isometric or isotonic or isokinetic or endurance or
kinesiotherap$).mp. (3621760)
28 relaxation therapy/ (6260)
29 (exercise adj2 (grading or pacing)).mp. (191)
30 behavior therapy/ (26836)
31 orthotic devices/ (6354)
32 exp drug therapy/ (1261528)
33 cognitive therapy/ (21880)
34 or/23-33 (4918512)
35 11 and 22 and 34 (63)
36 exp *neoplasms/ (2682771)
37 35 not 36 (62)
38 remove duplicates from 37 (56)
Appendix 3. Embase Ovid SP search strategy




2 double-blind procedure.sh. (139660)
3 single-blind procedure.sh. (29379)
4 randomized controlled trial.sh. (467233)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1418321)
6 trial.ti. (228280)
7 or/1-6 (1579561)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1664741)
9 animal/ or nonanimal/ or animal experiment/ (3783510)
10 9 not 8 (3138210)
11 7 not 10 (1452500)
12 limit 11 to (conference abstracts or embase) (1224945)
13 Motor Neuron Disease/ or Amyotrophic Lateral Sclerosis/ (36673)
14 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (11958)
15 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (195)
16 charcot disease.tw. (26)
17 amyotrophic lateral sclerosis.tw. (24487)
18 or/13-17 (40610)
19 Fatigue/ or fatigue.mp. (208432)
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20 (tired$ or weariness or weary or exhaust$ or lacklustre or astheni$ or lethargic or languidness or languor or lassitude or listlessness).mp.
(103622)
21 ((lack or loss or lost) adj2 (energy or vigour or vigour)).mp. (6165)
22 19 or 20 or 21 (301269)
23 18 and 22 (881)
24 fatigue/dm, dt, th [Disease Management, Drug Therapy, Therapy] (3699)
25 exp Exercise Therapy/ (63627)
26 exp Physical Therapy Modalities/ (75181)
27 rehabilitation.mp. or Rehabilitation/ (307922)
28 (exercise or train or activity or physical or exercise or strength or sports or isometric or isotonic or isokinetic or endurance or
kinesiotherap$).mp. (4764154)
29 relaxation therapy/ (9816)
30 (exercise adj2 (grading or pacing)).mp. (217)
31 behavior therapy/ (40378)
32 orthotic devices/ (5247)
33 exp drug therapy/ (2093882)
34 cognitive therapy/ (42135)
35 or/24-34 (6755799)
36 11 and 23 and 35 (91)
37 exp *neoplasm/ (2854492)
38 36 not 37 (85)
39 remove duplicates from 38 (80)
Appendix 4. PsycINFO Ovid SP search strategy
Database: PsycINFO <1806 to August Week 4 2017>
Search Strategy:
--------------------------------------------------------------------------------
1 (random$ or rct or cct or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$)
or assign$ or allocat$ or volunteer$).tw. (308023)
2 amyotrophic lateral sclerosis/ (3288)
3 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (1243)
4 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (49)
5 or/2-4 (4107)
6 (fatigue or tired$ or weariness or weary or exhaust$ or lacklustre or astheni$ or lethargic or languidness or languor or lassitude or
listlessness).mp. (38405)
7 ((lack or loss or lost) adj2 (energy or vigour or vigour)).mp. (619)
8 6 or 7 (38838)
9 1 and 5 and 8 (3)
Appendix 5. CINAHL Plus EBSCO host search strategy
Tuesday, September 05, 2017 9:18:08 AM
S30 S28 AND S29 2
S29 EM 20161007- 248,271
S28 S27 Limiters - Exclude MEDLINE records
Interface - EBSCOhost Research Databases
Search Screen - Advanced Search
Database - CINAHL Plus 20
S27 S18 AND S23 AND S26 98
S26 S24 OR S25 40,470
S25 (lack or loss or lost) N2 (energy or vigour or vigour) 665
S24 fatigue or tired* or weariness or weary or exhaust* or lacklustre or astheni* or lethargic or languidness or languor or lassitude or
listlessness 39,965
S23 S19 or S20 or S21 or S22 7,560
S22 (Lou Gehrig* W5 syndrome*) or (Lou Gehrig* w5 disease*) 42
S21 "amyotrophic lateral sclerosis" 3,397
S20 motor neuron disease or motor neurone disease or motoneuron* disease or motorneuron* disease 1,431
S19 (MH "Motor Neuron Diseases+") 6,785
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 990,862
S17 ABAB design* 102
S16 TI random* or AB random* 223,975
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S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial or
sham? or dummy) ) 447,954
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 171,024
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 59,093
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind* or mask*) )
34,513
S11 PT ("clinical trial" or "systematic review") 132,151
S10 (MH "Factorial Design") 1,005
S9 (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") 315,906
S8 (MH "Meta Analysis") 28,517
S7 (MH "Solomon Four-Group Design") or (MH "Static Group Comparison") 92
S6 (MH "Quasi-Experimental Studies") 8,580
S5 (MH "Placebos") 10,318
S4 (MH "Double-Blind Studies") or (MH "Triple-Blind Studies") 36,327
S3 (MH "Clinical Trials+") 220,329
S2 (MH "Crossover Design") 15,021
S1 (MH "Random Assignment") or (MH "Random Sample") or (MH "Simple Random Sample") or (MH "Stratified Random Sample") or (MH
"Systematic Random Sample") 77,258
Appendix 6. ERIC EBSCO host search strategy
Interface - EBSCOhost Research Databases
Search Screen - Advanced Search
Database - ERIC
Tuesday, September 05, 2017 9:40:20 AM
S8 S4 AND S7 1
S7 S5 OR S6 3,217
S6 (lack or loss or lost) N2 (energy or vigour or vigour) 97
S5 fatigue or tired* or weariness or weary or exhaust* or lacklustre or astheni* or lethargic or languidness or languor or lassitude or
listlessness 3,125
S4 S1 OR S2 OR S3 47
S3 (Lou Gehrig* W5 syndrome*) or (Lou Gehrig* w5 disease*) 6
S2 amyotrophic lateral sclerosis 33
S1 motor neuron disease or motor neurone disease or motoneuron* disease or motorneuron* disease
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We included an explanation of the process of downgrading the evidence in 'Summary of findings' tables.
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Medical Subject Headings (MeSH)
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